Join: GEN Drug Discovery Theatre at BIOTECHNICA 2010

genlogo AntisensePharma_logo Biotechnica


Join the session TGF-β – an important target in cancer diseases!



More than 30 years after its discovery, Transforming Growth Factor beta (TGF-β) engages cell biologists, immunologist, developmental biologists, and cancer researchers. TGF-β and cancer were linked from the start: Highly aggressive tumors produce huge amounts of TGF-β - which enhances migration and metastasis of tumor cells, mediates angiogenesis and is known as one of the strongest immunosuppressors.


But what about the development of therapeutics against this obvious oncological target?


Genetic Engineering & Biotechnology News presents


TGF-β – an important target in cancer diseases


followed by an interactive panel discussion at the BIOTECHNICA 2010


Hall 9, Stand B23

Tuesday, 5th of October 2010

3:30 p.m. – 5 p.m.


Speakers & Topics:


Prof. Peter ten Dijke, professor of molecular cell biology at Leiden University, The Netherlands

TGF-β and its role in aggressive cancer diseases


Dr. Piotr Jachimczak, physician and senior scientific advisor at Antisense Pharma, Regensburg

Therapies targeting TGF- β – an overview


PD Dr. Peter Hau, section leader of the neurooncology department, University of Regensburg

Inhibition of TGF- β2 in high-grade glioma patients –results of a clinical Phase IIb study



Dr. Hubert Heinrichs, CMO at Antisense Pharma GmbH, Regensburg, Germany


Do you want to join the session, are you interested in getting the supporting material or do you have further questions? Please don’t hesitate to contact Carolin Nolte at Antisense Pharma at This email address is being protected from spambots. You need JavaScript enabled to view it. or  + 49 941 92013 175.


We are looking forward to welcome you on the 5th of October!


About Genetic Engineering & Biotechnology News (GEN)

GEN has retained its position as the number one biotech publisher around the globe since its launch in 1981. GEN publishes a print edition 21 times a year and has additional exclusive editorial content online, like news and analysis as well as blogs, podcasts, webinars, polls, videos, and application notes. Additionally, GEN hosts a networking platform called GENconnect, which comprises Communities such as All Things PCR, Next-Generation Sequencing, Biomarkers, and more. GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.


About GEN Drug Discovery Theatre at Biotechnica 2010

GEN sponsors a "Discovery Theatre", which features a series of 45-minute panel discussions each led by a moderator. The focus is on the development and application of novel drug discovery tools, techniques, methodologies, strategies, and products.

Since large pharma companies have seen their own new drug pipelines dry up, technology transfer of promising newly discovered compounds from academia and small biotech companies to international drug firms will be a key topic of discussion. A wide range of scientific and technical issues will be explored, including those involving ADME/TOX, assay development, biomarkers, gene expression, microarrays, nanotechnology, PCR, RNAi, next-generation sequencing, cell based assays, lead discovery and validation, and many more.


About Biotechnica

BIOTECHNICA is Europe's leading annual event for biotechnology and the life sciences. It covers the entire spectrum of biotechnology, including fundamentals and equipment, bio-informatics and services, and addresses all five major fields of application, i.e. pharmaceuticals/medicine, industrial manufacturing, food, agriculture and the environment.


About Antisense Pharma GmbH

Antisense Pharma is a biopharmaceutical company located in Regensburg, Germany. The company focuses on targeted therapies for malignant tumors and is dedicated to discovering and developing drugs based on antisense technology for worldwide commercialization. The medications specifically block the synthesis of key cancer proteins. Antisense Pharma has clinical trials running that involve patients with brain tumors, advanced pancreatic carcinoma, malignant melanoma and colorectal carcinoma. An international pivotal Phase III study in anaplastic Astrocytoma patients (SAPPHIRE) is ongoing. Therapies for other indications are under preclinical development. The company has been honored with the German Founder‘s Award and the Bavarian Innovation Award and in 2009 received the Innovation Prize TOP 100. For further information on Antisense Pharma please visit



Carolin Nolte

ANTISENSE PHARMA GmbH | Josef-Engert-Str. 9 | 93053 Regensburg, Germany

Phone + 49 941 920 13 175 | Fax +49 941 920 13 29 | This email address is being protected from spambots. You need JavaScript enabled to view it.

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.